Introduction

47
Human immunodeficiency virus (HIV) infection is a retroviral infection that causes acquired
The major drivers for regimen modifications world-wide included treatment failure and adverse drug Other studies conducted in South Africa, have reported higher rates of treatment modification in 88 stavudine and zidovudine containing regimens compared to tenofovir-containing regimens [20, 22] .
89
In order to ensure antiretroviral drug safety, it is essential to understand drug effects, prescribing clinic and patients from different areas who do not want to utilize nearest clinics due to stigma).
105
Witbank clinic is a comprehensive primary health care centre which offers all the primary health care 
Definitions
157
We defined treatment discontinuation as stopping any antiretroviral drug or regimen temporarily or 158 permanently due to toxicity. Regimen changing/modification/switching was defined as changing the
159
ART regimen from one standardised regimen to another or to a non-standardised (individualised) 160 regimen. Substitution of a drug was defined as replacement of one or more drugs within the regimen 161 either standardised or non-standardised to another more potent drug. 167 Data analysis 169 We described categorical variables using proportions and frequencies and compared them using Fig 1) . on TDF-based regimens (51%, n=1,054), 35% (n=718) on d4T-based and 10% (n=212) on AZT-209 based regimens. Some patients were initiated on non-standardised regimens (3%, n=61) (Table 1) .
210
The age group with the highest frequency was 25-34 years (38%), followed by 35-44 years (32%).
211
These age groups had higher frequencies in all ART initiation regimens. The frequencies of regimen changing for d4T-based, AZT-based, and non-standardised regimens 227 were 68% (n=490), 44% (n=93), and 34% (n=21), respectively. Majority of patients were on TDF-228 based regimens, however, the frequency of changing (17%, n=179) was lower than all other regimens.
229
Females accounted for 66% (n=521) of the patients who had their initial ART regimens changed. (Table 2 ). There were 8% (n=158) who had their treatment discontinued 234 temporarily. Forty-one percent (n=64) of those who had their ART discontinued temporarily also had 235 their regimens changed.
236
The overall incidence rate of initial ART regimen changes was 10.0 per 100 person-years (PYs) (95% in patients initiated on d4T (13.6; 95% CI 12.5-14.9), AZT (8.0; 95%CI 6.6-10.0), non-standardised 245 (7.2; 95% CI 4.7-11.0) as compared to TDF (6.5; 95% CI 5.6-7.5) per 100 PYs.
246
Kaplan-Meier (KM) survival plots for the length of time after ART initiation until occurrence of the 247 first regimen change were presented for the different backbone NRTIs groups (Fig 2) . There was a 248 significant difference in survival times between the backbone NRTIs groups (log rank test=0.001).
249
Patients on TDF-based regimens had a better survival on the initial ART regimen, than those on d4T 250 and AZT based regimens. Patients on d4T based regimens had the shortest survival time. 
251
Reasons for changing ART
255
The main reason for initial ART regimen changing was ADRs 60%, followed by prescriber's decision 256 37%, drug toxicity 26% and treatment failure 15%. Stavudine-based regimens accounted for the 257 majority of ART regimen changes due to toxicity (86%, n=176) and ADRs (81%, n=267).
258
Approximately half of the patients with treatment failure (58%) were initiated on d4T-based 259 regimens. Among the pregnant women who had their regimens changed, 59% (n=20) were on d4T-260 based regimens. Patients on tenofovir-based regimens were changed from a non-combined drugs to 261 a fixed-dose combination (FDC) pill. Guidelines related (7.5%) and unavailability of ART (2.6%)
262
were the other reasons for ART regimen changing (Table 3) . neurological problems and rash accounting for 43% (n=235), 34% (n=189), 22% (n=124), 20%
282
(n=109) and 14% (n=79) respectively (Table 4) . Kaplan-Meier plots of the probability of changing initial ART regimen show that patients who did 288 not experience ADRs had better survival rates on the initial ART regimen than those who experienced 289 ADRs (Fig 3) .
290
Predictors of ART changing
291
There was evident increase in ART regimen changing attributable to ADRs, drug toxicity, treatment 292 failure and prescribed initiation regimens. We analysed the time to the first incidence on initial ART 293 regimen changing using Kaplan-Meier plots, stratified by backbone first-line antiretroviral regimens 294 (Fig 2) . Using TDF-based regimens as reference, the results from Cox proportional hazard analysis 295 found patients using d4T-based (adjusted Hazard ratio (aHR): 2.3; 95% CI 1.8-2.9, p<0.001), AZT
296
(aHR: 1.5; 95% CI 1.0-2.2, p=0.026) and non-standardised (aHR 1.6; 95%CI 0.9-2.9, p=0.113)
297
regimens as significantly associated with regimen changing. Other predictors of ART regimen 298 changing included drug toxicity (aHR 2.6; 95% CI 2.1-3.1, p<0.001), ADRs (aHR 2.1; 95%CI 1.3- and initiation regimens that was included in the Cox proportional hazard model (Table 5) . This study reports the occurrence of and the reasons for initial ART regimen changing in a The majority of the patients were initiated on TDF-based (51%) regimens followed by d4T-based The overall incident rate of ART regimen changes in the current study was comparable with the 343 incident rate reported in Nairobi (11.1 per 100 PYs) [25] . The current study reports the overall 344 incident rate of 10.0 per 100 PYs. The exposure time for patients initiated on non-standardised 345 regimens was lower than all other regimens. The specific incident rates of regimen changes for d4T,
346
AZT and TDF base regimens were 13.0, 8.0 and 6.5 respectively. We observed that TDF was more 347 tolerated than d4T and AZT. The significant difference in changing rates were further observed on 348 the KM plot that indicated the higher rate of changing the initial ART regimens in stavudine findings were also comparable with the study conducted in Nairobi [25] .
352
With the improvement in ART over years, the reasons for regimen modification changed from merely 354 treatment failure and drug resistance to several factors [Günthard] . 
